0QF:FRA
Moderna Inc
167,36 €
arrow_downward
-0,92%(-1,56) 1 d.
2. okt., 22:00:00 GMT+2 · EUR
search
Visi simboli
| Simbols | Cena | Izmaiņas | % izmaiņu |
|---|
insights_autoNotiek galveno ieskatu ģenerēšana par šādu tēmu: 0QF…
Atvērt
169,66 €
Augsta
171,20 €
Zema
163,30 €
Tirgus kapitalizācija
75,86 mljrd.
Vid. apjoms
2,99 tūkst.
Apjoms
919,00
Augstākā 52 ned.
183,40 €
Zemākā 52 ned.
19,26 €
Darbinieku skaits
5 tūkst.
Atvērt
169,66 €
Augsta
171,20 €
Zema
163,30 €
Tirgus kapitalizācija
75,86 mljrd.
Vid. apjoms
2,99 tūkst.
Apjoms
919,00
Augstākā 52 ned.
183,40 €
Zemākā 52 ned.
19,26 €
Darbinieku skaits
5 tūkst.
Ziņas un raksti
No tīmekļa avotiem un ziņu partneriem
AD HOC NEWS
·
pirms 39 minūtēm
Moderna stock gained 0.57 percent as Nasdaq-100 entry nears
Stocktwits
·
pirms 13 stundām
SLS, IBRX Stocks Draw Retail Chatter As MRNA Lands A Nasdaq-100 Spot – ‘It Will Be SLS Next’
Simply Wall Street
·
pirms 1 dienas
Moderna (MRNA) Stock Looks Too Expensive For Its Sales Story
Investing.com
·
pirms 2 dienām
Moderna to join Nasdaq-100 index on Oct. 9, replacing Warner Bros.
Profils
Moderna, Inc. is an American pharmaceutical and biotechnology company based in Cambridge, Massachusetts, that focuses on RNA therapeutics, primarily mRNA vaccines. These vaccines use a copy of a molecule called messenger RNA to carry instructions for proteins to produce an immune response. The company's name is derived from the terms "modified", "RNA", and "modern".
The company's commercial products are the Moderna COVID-19 vaccine sold under the brand names Spikevax and Mnexspike, a respiratory syncytial virus vaccine sold under the brand name Mresvia, and an influenza vaccine sold under the brand name Mflusiva. The company has 44 treatment and vaccine candidates, of which 37 have entered clinical trials. Candidates include possible vaccines for influenza, HIV, Epstein–Barr virus, the Nipah virus, chikungunya, human metapneumovirus, varicella zoster virus, as well as a cytomegalovirus vaccine, a Zika virus vaccine funded by the Biomedical Advanced Research and Development Authority, and three cancer vaccines.
In May 2026, Time ranked Moderna first in their list of the World's Most Impactful Companies. Wikipedia
Par “Moderna Inc”
ĢenerāldirektorsStéphane Bancel
Darbinieki4,7 tūkst.
Dibināšanas datumssept. 2010
Galvenais birojs-
Sektors-
Tīmekļa vietnemodernatx.com